Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Why Altimmune Was Such a Robustly Healthy Stock on Thursday Motley Fool - Thu Dec 19, 5:35PM CST

Altimmune (NASDAQ: ALT) had some encouraging news to share with the world as the trading week drew near a close on Thursday. The biotech announced that it will soon ascend to an important, specialized...

ALT : 8.25 (+0.86%)
Altimmune, Inc. Added to Nasdaq Biotechnology Index Effective December 23, 2024 Quiver Quantitative, Inc. - Thu Dec 19, 4:52PM CST

Altimmune, Inc. will join the Nasdaq Biotechnology Index on December 23, 2024, highlighting its progress and upcoming clinical milestones.Quiver AI SummaryAltimmune, Inc., a clinical-stage biopharmaceutical...

ALT : 8.25 (+0.86%)
Altimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock Rebounds Stocktwits - Thu Dec 19, 8:58AM CST

The NBI serves as the basis for the iShares NASDAQ Biotechnology Index Fund and is reevaluated annually.

IBB : 132.73 (+1.16%)
ALT : 8.25 (+0.86%)
Altimmune Added to Nasdaq Biotechnology Index GlobeNewswire - Thu Dec 19, 6:30AM CST

ALT : 8.25 (+0.86%)
Altimmune, Inc. Announces Presentation of Pemvidutide Body Composition Data at International Conference on Sarcopenia and Cachexia Quiver Quantitative, Inc. - Mon Dec 2, 4:48PM CST

Altimmune's CMO will present Phase 2 trial data on pemvidutide for obesity at an upcoming conference in Washington, D.C.Quiver AI SummaryAltimmune, Inc. has announced that its Chief Medical Officer, Dr....

ALT : 8.25 (+0.86%)
Altimmune Stock Up More Than 25% in a Month: Here's Why
Altimmune Stock Up More Than 25% in a Month: Here's Why Zacks Investment Research - Mon Dec 2, 9:38AM CST

Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual receptor agonist for treating obesity and metabolic dysfunction-associated steatohepatitis...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
ALT : 8.25 (+0.86%)
SPRO : 0.9551 (-4.30%)
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders GlobeNewswire - Mon Dec 2, 6:30AM CST

ALT : 8.25 (+0.86%)
Altimmune to Participate at Two Upcoming Investor Conferences GlobeNewswire - Tue Nov 26, 6:30AM CST

ALT : 8.25 (+0.86%)
Altimmune, Inc. Reports Promising Phase 1b Trial Results for Pemvidutide in Reducing Cardio-Inflammatory and Hepato-Inflammatory Lipids in Patients with MASH Quiver Quantitative, Inc. - Fri Nov 15, 8:16PM CST

Pemvidutide showed significant reductions in inflammatory lipids, supporting its potential benefits for metabolic dysfunction-related conditions.Quiver AI SummaryAltimmune, Inc. announced favorable results...

ALT : 8.25 (+0.86%)
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 GlobeNewswire - Fri Nov 15, 10:00AM CST

ALT : 8.25 (+0.86%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot